Faeth Therapeutics Trading Activity
- Price movement: Shares of Faeth Therapeutics Inc. (FTH) rose 3.4 % during the 24‑hour period ending at 07:51 PM Central Europe on Tuesday, 20 May 2026.
- Current price: The stock trades at approximately USD 20.71 on major exchanges.
- Shares outstanding: 25.8 million.
- Market capitalization: USD 485.8 million.
- Volume: About USD 6.8 million of shares were traded in the last 24 hours.
- Month‑to‑date performance: Since the close of the previous month, the share price has fallen 41.6 %.
- Moving average: The simple moving average over the last 200 days is USD 24.78.
- 52‑week range: The highest price was USD 42.14 on 08 September 2026; the lowest was USD 7.45 on 05 December 2025.
Corporate Update
Faeth Therapeutics Inc. announced that it will present preclinical data on its lead program, PIKTOR, at the upcoming European Society for Medical Oncology (ESMO) Congress in Madrid.
- The presentation will focus on the efficacy of the oral combination of serabelisib and sapanisertib in hormone‑receptor positive, HER2‑negative breast‑cancer models, evaluating both monotherapy and combinations with established endocrine and cell‑cycle inhibitors.
- Comparative studies with another PI3K‑AKT‑mTOR pathway inhibitor will also be shown.
- The data are intended to inform the ongoing Phase 1b/2 clinical trial of PIKTOR in breast cancer and a separate Phase 2 study in advanced endometrial cancer.
- The company highlighted the potential of its multi‑node inhibition strategy to address resistance mechanisms that limit single‑node therapies.
- No additional corporate actions or financial transactions were reported.
Recent Performance of Peer Stocks
| Ticker | 24‑hour change | Current price (USD) | Market cap (USD mn) | Notes |
|---|---|---|---|---|
| VEL (Velocity) | –1.36 % | 14.90 | 580.8 | P/E = 5.36 |
| OLMA (Olema) | +8.05 % | 7.52 | 575.7 | Analyst commentary highlights growing drug sales and pipeline progress |
| REAX (Real Remax) | –3.20 % | 16.94 | 582.1 | – |
| KIDS (Orthopediatrics) | +0.36 % | 22.85 | 579.6 | – |
| LMB (Limbach) | –0.29 % | 48.28 | 578.6 | P/E = 19.55 |
Company Profile
Faeth Therapeutics Inc. operates as a clinical‑stage immunotherapy company focused on developing next‑generation cancer therapies. The firm emphasizes research and development of novel treatments aimed at improving outcomes for patients with various malignancies.
